Why Achillion Pharmaceuticals (ACHN) Is Spiking Today

NEW YORK (TheStreet) -- Achillion Pharmaceuticals (ACHN) shares are rising, up 14.4% to $7.39 on Monday, after having its price target raised to $22 from $6 dollars by analysts at Maxim who also reiterated their "buy" rating. 

The increased price target stems from the firm's faith in the intellectual property of the biopharmaceutical company's Hepatitis C nucleotide.

Must ReadWarren Buffett's 25 Favorite Stocks 

ACHN Chart

ACHN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.



If you liked this article you might like

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence